Osteogenic Induction of Wharton's Jelly-Derived Mesenchymal Stem Cell for Bone Regeneration: A Systematic Review.
1. Introduction1.1. Human Umbilical Cord. About 25 years ago, the umbilical cord was considered to be a type of medical waste, until it was found to be a rich source of stem cells [1]. The abundance of stem cells and the ease of isolation have become deciding factors while choosing the source of adult stem cells. The human umbilical cord (HUC) is approximately 65 cm in length and 1.5 cm in diameter [2, 3]; it connects the fetus to the mother and supplies nourishment. The cord is covered by single or multiple layer of squamous cubic epithelial cells derived from the developing amnion [4-6]. The HUC contains two arteries and one vein, which are surrounded by a mucoid connective tissue known as Wharton's jelly (WJ) [7]. This mucous connective tissue is made up of mucopolysaccharides that are hyaluronic acid and chondroitin sulphate [8]. Basically, WJ can be divided into 4 layers with the outer layer being the amniotic epithelium followed by cord lining WJ and intermediate WJ. The inner layer of WJ is also known as perivascular WJ which contains arteries and vein [7] (Figure 1).
It has been reported that WJ also contains myofibroblastlike stromal cells, collagen fibers, proteoglycans, fibroblasts, and macrophages. WJ has garnered interest due to its availability, the noninvasive method of collection, and high cell yields. It has been demonstrated that mesenchymal stem cells (MSCs) isolated from the umbilical cord express matrix receptors (CD44 and CD105) and integrins (CD29 and CD51), but not hematopoietic lineage markers (CD34 and CD45) [9]. These cells exhibit a phenotype similar to that of mesenchymal stem cells from other tissue sources [10]. According to the International Society for Cellular Therapy (ISCT), stem cells should demonstrate plastic adherence, not expressing hematopoietic markers, and be able to commit to the adipogenic, osteogenic, and chondrogenic lineage [11]. WJ-MSCs have a huge advantage where the phenotype and stemness are remained despite being in a long-term culture. This enables a mass production of cells which is usually required for regenerative medicine [12].
1.2. WJ-MSCs and Their Potential in the Treatment of Diseases. WJ, also known as substantia gelatinea funiculi umbilicalis, consists of fibroblast-like cells and mast cells that are embedded in proteoglycans, mainly hyaluronic acid. The cells are thought to be trapped in WJ during the early stage of embryogenesis, when they migrate from the aortic gonadotropin mesonephric region to the fetal liver through the umbilical cord [13]. WJ-MSCs have many advantages over other types of stem cells, including higher proliferation rates and broader multipotency. WJ-MSCs are able to differentiate into many cell types such as adipocytes [14, 15], osteoblasts [14,16], hepatocytes [17], chondrocytes [18], and neural cells [19, 20]. Interestingly, it has also been demonstrated in a three-dimensional model that WJ-MSCs are able to differentiate in vitro into cornea epithelial-like cells, which may offer a solution for patients with limbus stem cell deficiency [21].
Cui and colleagues have successfully improved cognitive function in a mouse model of Alzheimer's disease using intravenously delivered WJ-MSCs, which reduced oxidative stress and promoted hippocampal neurogenesis [20]. In a clinical trial conducted by Hu and colleagues, an intravenous infusion of WJ-MSCs in type 2 diabetes mellitus patients improved the function of islet [micro]-cells and reduced the incidence of diabetic complications [22]. Additionally, WJ-MSC therapy is now used to treat corneal epithelial, stromal, and endothelial disorders apart from the conventional intervention such as surgery, ionizing radiation, or drug treatment [23, 24].
1.3. Immunomodulatory Aspect of WJ-MSCs and BM-MSCs. WJ harbours MSCs that possess a similar phenotype as harvested from the bone marrow and other sources. WJMSCs do not express HLA-DR and costimulatory molecules CD40, CD80, and CD86 which are essential for the activation of T-cells [1, 2, 9, 25-27]. WJ-MSCs have been proven to have lower immunogenicity than BM-MSCs as depicted by Weiss et al. [1] who conducted an experiment using mixed lymphocyte reaction (MCR) assay [26]. In a study conducted by Prasanna et al. and Deuse et al., both consistently showed low HLA-DR expression compared to BM-MSCs after stimulation with IFN-[gamma] and proinflammatory cytokines [28, 29]. In normal culture conditions, HLA-DR is not expressed; hence, the activation of T-cell is inhibited, reducing the risk of allograft rejection which potentially makes it safe for human transplantation.
It is documented that BM-MSCs harbour viruses, which is a major drawback in clinical application. There are reports from patients who undergo BM-MSC transplant who are infected with viral infection as a complication of the cellbased therapy [9]. Interestingly, the virus can escape from detection therefore increasing the morbidity and mortality [30]. Moreover, there are various diseases such as aplastic anemia, leukaemia, and bone marrow failure that impedes the application of BM-MSCs in therapy [31].
1.4. WJ-MSC Homing and Migration for Bone Healing. Generally, MSCs are known to migrate towards the injury site and help the healing process. The migration process, known as homing, is defined as the arrest of MSCs within the vasculature of a tissue before it crosses over the endothelium [24, 32]. As for now, the mechanism of MSC homing is still vague and BM-MSCs are postulated to have a mechanism similar to leukocyte homing. The mechanism is initiated when MSCs collide with the endothelium rolling, causing a slackening of cells in the blood flow. The G-protein-coupled receptors activated the cells and activated integrin mediation, causing activation-dependent arrest. The process is completed with the transmigration of the cells through the endothelium and the underlying basement membrane [33]. There are several factors that contribute to the homing mechanism which are growth factor expression as well as chemokine and extracellular matrix receptors on the MSCs' surfaces [34].
In a study conducted by Granero-Molto et al., MSCs are migrated to the fracture site via the CXCR4 receptor causing improvement of biomechanical properties and increasing the cartilage and bone of the callus [24]. Zwingenberger et al. demonstrated that the combination of the SDF-1 released and bone morphogenetic protein 2 contributes to the migration of the stem cell [35]. This occurrence markedly boosts bone regeneration. Apart from that, MSCs are also recruited towards wear-particle-related osteolysis which is indicated by the inflammatory macrophage that is also the chemokine CC receptor (CCR) 1 of MSCs [30, 36]. The MSCs are demonstrated to increase bone mineral density and decrease the osteolytic process [37].
1.5. Cellular Mechanism of Bone Remodelling for Bone Regeneration. Bone repair or bone regeneration is characterized by a series of tissue transformation mechanisms including resorption and formation of hard and soft tissue. Therefore, mineralized tissue remodelling is required for the involvement of various cell types including osteoclast and osteoblast. Osteoblasts are bone-forming cells that can be found at the surface of bone, while osteoclasts are multinucleated bone-resorbing cells derived from bone marrow stem cells [38]. Bone remodelling is a cyclical process in which bone undergoes consistent renewal to ensure the replacement of primary bone, to maintain calcium homeostasis, and especially to heal ischemic and microfractured bone [7, 20, 32-34, 39]. This process requires a correct balance of bone resorption and bone formation and thus involves osteoclasts and osteoblasts, respectively.
Bone remodelling consists of five consecutive phases: (1) the resorption phase, where osteoclasts break down the bone tissue, resulting in mineral release; (2) the reversal phase, where mononuclear cells appear on the bone surface; (3) the formation phase, where osteoblasts trapped in the bone matrix become osteocytes; (4) the mineralization phase, where osteocytes produce type I collagen and other substances that make up the bone extracellular matrix; and (5) the termination phase [38, 40]. Resorption is initiated by osteoclast progenitors that are recruited and disseminated into the bloodstream. These cells proliferate and differentiate into mature osteoclasts, aided by osteoblast stromal cells via cell-to-cell interactions. These osteoblasts express two cytokines, i.e., receptor activator of NF-kB ligand (RANKL) and osteoprotegrin (OPG), involved in osteoclast progenitor cell differentiation. Under parathyroid hormone (PTH) stimulation, RANKL will bind to RANK, a cytoplasmic membrane receptor on osteoclast progenitor cells, to stimulate their fusion, differentiation, and activation. In contrast, OPG binds to RANKL to counterbalance the effect of RANKLRANK, which thereby determines the extent of bone resorption. These events are important in maintaining bone homeostasis [41] (Figure 2). Bone resorption is terminated when osteoclasts undergo apoptosis and the reversal phase is initiated. Reversal cells may thus represent the missing link necessary to understand the coupling between bone resorption and formation. Researchers have found that reversal cells colonizing the resorbed bone surface are immature osteoblastic cells that gradually mature into bone-forming osteoblasts during the reversal phase and prepare the bone surface for bone formation [42].
1.6. Molecular Mechanism of Bone Remodelling for Bone Regeneration. The differentiation of MSCs depends on which signalling pathway is activated. Apart from osteoblasts, WJMSCs have also been demonstrated to differentiate into other mesenchymal cell lineages such as hepatocytes [43], chondrocytes [18, 44], and adipocytes [14, 15]. The markers for osteogenic differentiation are alkaline phosphatase (ALP), an early marker of osteogenic differentiation and mineralization, and RUNX2, a runt domain-containing transcription factor that is crucial for osteogenic differentiation and bone formation. The activation of RUNX2 triggers COL1 (collagen type 1), osteopontin (OPN), and osteocalcin (OC), which are osteoblast-specific markers. OPN is expressed later in the differentiation stage [45, 46]. Both OPN and COL1 are synthesized by osteoblasts. OC is also expressed later and is important for maintaining bone resorption. Osterix (Osx) is a downstream factor of Runx2 that binds to activated NFAT2 in bone development [47]. A study by Zhou et al. explored the function of Osx where it regulates bone homeostasis after birth for bone and cartilage formation [26].
In osteoblasts, lineage-specific gene expression control by specific transcription factors, i.e., Cbfa-1/RUNX2, acts to regulate osteoblastic specific gene expression [48]. Cbfa1/RUNX2 is required for osteoblast differentiation, since Cbfa-1 knockout mice display impaired or even absent bone formation [49, 50]. This transcription factor contains a runt DNA-binding domain, which can bind to DNA as a monomer or as a subunit of a monomeric complex. It binds to various enhancers and promoters, including those for the genes encoding osteocalcin, osteopontin, bone sialoprotein, and GM-CSF. The expression of these proteins contributes to the bone matrix, leading to the maturation of osteoblasts. These genes can also be used as markers for different stages of osteoblast development [51-53].
The expression of transcription factors is controlled by several pathways that are activated by growth factors (GFs) that bind to a specific receptor. These growth factors include fibroblast growth factor (FGF), transforming growth factor-[micro] (TGF-[beta]), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) [54]. It has been reported that these GFs are responsible for regulating the expression of Cbfa-1/RUNX2 via the MAPK [55], ERK [52], and PI3K-Akt pathways [54, 56]. GF binding to its receptor tyrosine kinase (RTK) activates a downstream signaling cascade. The activated RTK activates class I phosphatidylinositol 3-kinase (PI3K) or guanosine nucleotide-binding protein (Ras) and propagates the signal through direct binding or tyrosine phosphorylation. This then activates Akt/PKB, IkK/IkB, or Raf/MEK, which then activates NF-kB or MAPK, accordingly. Activated NF-kB and MAPK act through direct binding to phosphorylate ERK/JNK-cJun, which then activate Cbfa1/ RUNX2 gene expression. TGF-[beta] plays important roles in osteoblast precursor recruitment, FGF enhances osteoblast recruitment and proliferation, IGF is involved in the regulation of bone matrix synthesis and migration, VEGF regulates osteoblast differentiation, and PDGF is involved in osteoprogenitor migration [51, 52]. Cumulatively, the osteogenic differentiation capability owned by WJ-MSCs supplemented with specific GF is postulated to have a high potential for bone regeneration.
1.7. WJ-MSCs for Bone Regeneration. Albeit many have used WJ-MSCs in the studies, the safety and efficacy of its application are indecisive particularly in bone regeneration. There are several aspects that need to be considered prior to using WJ-MSCs that may influence the yield and its stemness potency. Different parts of the umbilical cord generated diverse frequencies of MSCs and cell populations [6-8, 57-59]. It is known that Runx2 plays a pivotal role in osteoblast differentiation. In a previous study, it has shown that WJMSCs have lower capability to differentiate due to the high level of RUNX2 but lower ALP expression. ALP is important for matrix maturation [60, 61]. WJ-MSCs also exhibited higher expression of pluripotent markers, OCT 4, SOX 2, and NANOG than in other parts of the umbilical cord [62]. From those findings, it can be postulated that regulation of Runx2 and pluripotent impedes ALP expression, thus needing a specific modulator that can serve as a molecular switch of WJ-MSCs' fate. Current study by Bustos and colleagues have demonstrated that JARID1B (Jumonji AT-rich interactive domain 1B) histone demethylase represses Runx2 in undifferentiated WJ-MSCs. In JARID1B knockdown murine, it can be seen that Runx2 is highly expressed and ready for osteogenic commitment indicating that this molecular mechanism is relevant to modulating osteoblastic lineage commitment [63].
1.8. Clinical Application of WJ-MSCs in Bone Regeneration. The current standard commonly used for bone tissue replacement is bone grafting obtained from patients themselves (autograft) or from other individuals (allograft). However, this has raised various effects including immunoreactivity and infection as well as procedure. WJ-MSCs have proved its capability to help in bone regeneration for clinical application. Qu et al. treated 36 patients with nonunion bone fracture with WJ-MSCs cultured with platelet-rich plasma (PRP) resulting in a faster recovery with no infection recorded compared to the other 36 patients with autoiliac treatment [64]. In another study, the intravenous injection of 3-5 million WJ-MSCs alleviated the condition of Becker muscular dystrophy patients with increased muscle strength, improved appetite, and also improved patient's gait [65]. Recently, a patient in Indonesia with infected nonunion bone is able to walk with no pain and no postoperative complications recorded after local implantation of 5 million cells supplemented with BMP-2 and hydroxyapatite [66]. A transplantation of autologous BM-MSCs and allogeneic WJ-MSCs in treating osteonecrosis of femoral head showed improvement where it relieved the pain and improved the joint function [67].
To this date, there are many various positive outcomes upon WJ-MSC treatment in clinical trials for different disorders including neurology [67], hematology [68], liver diseases [69], and particularly musculoskeletal diseases [65, 70]. WJ-MSCs have a huge potential to be used as an alternative treatment for bone disorders as it does not require ethical issues to obtain and it is alleviating patients' morbidities [71]. Since WJ-MSCs can retain the stemness and phenotypic stability compared to BM-MSCs, it has potency to be commercialised [72].
2. Methods
2.1. Search Strategy. A systematic review was conducted to systematically assess articles on the potential of WJ-MSCs for bone regeneration. Two databases were comprehensively used to search for relevant studies, i.e., Medline via Ebscohost and Scopus. For search term keywords, the combination of words used was "Wharton's jelly" AND "osteo*" OR "bone".
2.2. Selection Criteria. The year limit for searches was from 1961 to 2018, and only studies published in English were considered. The search outcomes identified all articles containing the words Wharton's jelly, umbilical cord, osteogenesis, osteogenic, and bone. Databases were searched individually to ensure all relevant studies were considered. The titles and abstracts were carefully screened for eligibility related to the topic of interest. Primary studies related to bone formation or bone regeneration were included. Review articles, news articles, letters, editorials, and case studies were excluded from the search.
2.3. Data Extraction and Management. Data were extracted from each eligible article by two reviewers. The selected papers were screened in several phases prior to inclusion. First, the titles that were not relevant to the topic were excluded. Next, the abstracts of the papers were screened, and unrelated studies were excluded. All duplicates were removed. The following data were summarized from the selected studies: (1) authors, (2) type of study, (3) subject/ sample, (4) induction factor, (5) methodology, (6) results, and (7) conclusions.
3. Results
3.1. Search Results. The primary searches identified 386 articles: 41 articles came from Medline and 345 articles were found in Scopus. To minimize bias and improve the strength of the related articles, two reviewers independently assessed the articles according to the inclusion and exclusion criteria. There were 244 articles removed as they were unrelated to either Wharton's jelly or osteogenesis/bone. A joint discussion was conducted to achieve consensus where differences emerged during the assessment. From the 142 remaining articles, 50 duplicates were removed before full articles were retrieved. From 92 articles, 74 articles were rejected based on the inclusion criteria as the articles were not primary studies, were not related to Wharton's jelly or osteogenesis, or were not available as full articles. Finally, a total of 18 studies were selected for data extraction in this review. The flow chart of the selection process is shown in Figure 3.
3.2. Study Characteristics. All studies were published between 1961 and 2018. An article reported on animal studies (in vivo), two articles on both in vitro and in vivo assessments, and 14 articles on in vitro studies. There were six articles which included scaffold fabrication in the study. Three out of six scaffold studies involved the optimization of the scaffold component for better bone regeneration. Eleven studies proposed a different type of tissue as the MSC source. From the generated data, we classified the articles into two subgroups: (1) chemical methods to promote osteogenesis and (2) physical methods (scaffolds) to promote osteogenesis. A summary of the studies is provided in Table 1.
4. Discussion
The database search provided 18 articles related to Wharton's jelly, umbilical cord, osteogenesis, osteogenic lineage, and bone. From these articles, various tissue sources were assessed for potential MSCs. Each of these sources was examined regarding MSC differentiation capacities into the adipogenic, chondrogenic, and osteogenic lineages. This review assessed the osteogenic potential of WJ-MSCs, which may have remarkable potential for bone regeneration in the clinic.
4.1. Mesenchymal Stem Cells: Potential Sources. Mesenchymal stem cells (MSCs) have attracted attention because of their unique plasticity and ability to differentiate into multiple cell lineages, i.e., osteoblasts, chondrocytes, and adipocytes, with potential for clinical usage. The bone marrow is a primary source of MSCs. However, it has been reported that the frequency as well as the differentiation potential of BM-derived MSCs (BM-MSCs) decline with increasing age [73]. Therefore, alternative sources of MSCs are needed, especially those that can be obtained noninvasively. Currently, various tissues are under consideration for MSC isolation, including adipose tissue, muscle, amniotic fluid, menstrual blood [74, 75], fetal blood [76], and periodontal ligaments (PDL) [61]. The human umbilical cord is a promising source of MSCs, as MSCs can be isolated either from the whole umbilical cord [16,77], the umbilical vein subendothelium [78], or WJ [14, 19, 74]. One group of researchers divided the umbilical cord into three anatomical segments, i.e., the maternal, middle, and fetal segments [79]. They demonstrated that MSCs from the maternal and fetal segments displayed greater viability, possessed significantly higher proliferation rates, and underwent more complete osteogenic differentiation, showing that these segments are a good source of MSCs for bone tissue engineering [79].
It is important to characterize cells derived from tissues to determine the type of cell population that exists in the preparation. A heterogeneous population could influence the differentiation properties, specifically the osteogenic potential of MSCs for bone regeneration. There are a few surface markers that are commonly reported for MSCs such as CD13, CD29, CD44, CD73, CD90, CD105, and CD166. MSCs do not express CD31, CD144, and CD309 (endothelial cell markers) or CD14, CD34, CD45, CD117, and CD133 (hematopoietic cell markers) [61, 79].
4.2. Wharton's Jelly Mesenchymal Stem Cells Undergo Osteogenic Differentiation. WJ-MSCs have been shown to have good potential for osteogenic differentiation. These cells display all features of functional osteocytes/osteoblasts based on osteogenic gene expression, extracellular matrix (ECM) mineralization, and the ability to adhere to a fabricated scaffold [80, 81]. Although Wj-MSCs have been broadly investigated, there are still problems when it comes to transplantation, as an immune response and rejection could occur [82]. In the database search, we only found one article that used autoserum for WJ-MSCs in vitro as a substitute for FBS to reduce the rejection rate. Autoserum is serum obtained from the umbilical cord blood. Baba et al. reported that the cell culture medium using autologous serum is superior in quality to medium using FBS. WJ-MSCs cultured in autologous serum exhibited successful osteoblastic and adipogenic differentiation. The WJ-MSCs were then transplanted subcutaneously into nude mice, and their potential to form bone was proven [16].
4.2.1. Chemical Induction. Seven studies out of 18 selected articles used chemical factors to promote osteogenesis in WJ-MSCs. Batsali et al. [83] demonstrated that WJ-MSCs are able to differentiate into the osteogenic lineage, although this was inferior compared to BM-MSCs. They demonstrated that WISP1, a canonical Wnt pathway target protein, was able to promote better osteogenic differentiation in WJ-MSCs [83]. A study by Szepesi et al. [61] showed that adipose tissue-derived mesenchymal stem cells (AT-MSCs) and periodontal ligament-derived mesenchymal stem cells (PDL-MSCs) have excellent potential for bone replacement applications and better endothelial differentiation ability as compared to WJ-MSCs [61]. The high degree of calcification in AT-MSCs and PDL-MSCs demonstrates that calcium deposition was better as compared to WJ-MSCs for generating vascularized bone grafts [61]. Similar findings were reported by [84] where AD MSCs were found to be superior to WJ-MSCs in terms of differentiating into the osteogenic lineage after 21 days compared. In a different study by Lim and colleagues, MSCs derived from different parts of the umbilical cord, i.e., the fetal, middle, and maternal segments, have the ability to differentiate into osteogenic lineage cells using the osteogenic medium consisting of dexamethasone, ascorbic acid, and [beta]-glycerophosphate. The fetal part was shown to have the best differentiation potential [79]. A study by Hsieh et al. [14] showed that BM-MSCs express more osteogenic genes compared to WJ-MSCs; conversely, WJ-MSCs are more responsible for angiogenesis [66]. Bone morphogenetic protein 2 (BMP-2) was used in a study by Hou et al. to promote osteogenic differentiation in WJ-MSCs [15].
4.2.2. Physical Induction. It is noteworthy that the microenvironment influences cell behaviour and leads to the production of a specific chemical composition that builds the ECM. Therefore, fabricated scaffolds have been actively investigated to find better materials and to produce the best structure of ECM-like components. From the database search, eight out of 18 articles investigated the fabrication of various scaffolds to test the potential of WJ-MSCs to promote complex bone regeneration. Various biomaterials were used to construct these scaffolds, ranging from collagen hydrogels [85] to bioactive glass [80]. 3D scaffolds have been documented as one of the best carriers for cell delivery in bone regeneration. The ideal scaffold should be osteoconductive, biocompatible, and bioresorbable; possess interconnected porosity; and promote cell binding/ attachment [82, 86].
The first phase in scaffold development used collagen as the main organic component in bone tissue for bone grafting [85]. Collagen type I can be isolated from Sprague-Dawley rat tails after processing and pelleting. Genipin has been selectively used for crosslinking collagen scaffolds to improve the stability and mechanical strength of the scaffolds in the culture medium [74]. Other crosslinkers have also been used, such as glutaraldehyde and formaldehyde. However, those have been reported to have some cytotoxic effects [87]. Calcium phosphate is another major constituent in bone that has been widely studied as a scaffold material for bone tissue engineering [88]. A study by Karadas et al. [74] produced an in situ mineralized collagen scaffold whereby, after cross-linking with genipin, the scaffold was immersed in a calcium and phosphate solution. As a result, highly integrated calcium phosphate minerals were successfully formed [74]. The combination of collagen I and III has also been reported to resemble the native ECM, where umbilical cord MSCs (UC-MSCs) were found to have better osteogenic potential compared to BM-MSCs [85]. In addition, porcine ECM, derived from the urinary bladder, has also been used as a biomaterial for scaffold preparation as it contains collagen, glycoproteins, glycosaminoglycans, and GFs [89].
Scaffold design then moved to the second phase, in which bioactive glass has been used as a scaffold in bone tissue engineering [80]. Kargozar and colleagues used a combination of bioactive glass/gelatin (BaG/Gel) scaffolds, aiming for a highly porous structure, which is considered ideal for bone substitution. A comprehensive physiochemical analysis showed that the structure had an intact, 3D porous microstructure with interconnected pores. It was also shown that the properties were very close to those of natural spongy bone [80]. They demonstrated that neovascularization was significantly better in the UC-MSCseeded scaffold when compared to the BM-MSC-seeded scaffold, indicating that the BaG/Gel scaffold is MSC type-dependent. A study by Todeschi and colleagues used hydroxyapatite (HA), beta-tricalcium phosphate ([beta]-TCP), or a mixture of the two [81] as the scaffold. They showed that a significantly higher number of blood vessels were present in the UC-MSC-seeded implants [81].
5. Conclusion
WJ-MSCs were first isolated by Mitchell et al. in 2003. During embryogenesis, totipotent cells such as primordial germ cells and hematopoietic stem cells migrate from the yolk sac through this region to populate target tissues in the embryo and fetus [90]. Characterization indicated that these cells are stem cells, as they express c-kit and can differentiate into neural cells. WJ-MSCs have similar proliferation and differentiation capacity and have multilineage differentiation potential [77], including osteogenesis. This review demonstrates that WJ-MSCs are capable of differentiation into osteoblasts, which may be useful for more effective bone fracture healing as these cells have been shown to migrate into and colonize a collagenous matrix. With the aid of 3D scaffolds, cell proliferation and survival are improved as these scaffolds provide structural stability similar to that of bone. However, MSCs have to be compatible with the scaffold prior to integration and incorporation into engineered bone.
https://doi.org/10.1155/2018/2406462
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
The research was carried out with the financial support of Universiti Kebangsaan Malaysia and AMRUS Medik Sdn. Bhd. through research grant numbers FF-2017-482 and FF-2017-020, respectively.
References
[1] M. L. Weiss and D. L. Troyer, "Stem cells in the umbilical cord," Stem Cell Reviews, vol. 2, no. 2, pp. 155-162, 2006.
[2] L. Raio, F. Ghezzi, E. di Naro et al., "Prenatal diagnosis of a lean umbilical cord: a simple marker for the fetus at risk of being small for gestational age at birth," Ultrasound in Obstetrics & Gynecology, vol. 13, no. 3, pp. 176-180, 1999.
[3] E. Di Naro, F. Ghezzi, L. Raio, M. Franchi, and V. D'Addario, "Umbilical cord morphology and pregnancy outcome," European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 96, no. 2, pp. 150-157, 2001.
[4] F. A. Meyer, Z. Laver-Rudich, and R. Tanenbaum, "Evidence for a mechanical coupling of glycoprotein microfibrils with collagen fibrils in Wharton's jelly," Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 755, no. 3, pp. 376-387, 1983.
[5] I. B. Copland, S. L. Adamson, M. Post, S. J. Lye, and I. Caniggia, "TGF-[beta]3 expression during umbilical cord development and its alteration in pre-eclampsia," Placenta, vol. 23, no. 4, pp. 311-321, 2002.
[6] M. Mizoguchi, Y. Suga, B. Sanmano, S. Ikeda, and H. Ogawa, "Organotypic culture and surface plantation using umbilical cord epithelial cells: morphogenesis and expression of differentiation markers mimicking cutaneous epidermis," Journal of Dermatological Science, vol. 35, no. 3, pp. 199-206, 2004.
[7] J. E. Davies, J. T. Walker, and A. Keating, "Concise review: Wharton's jelly: the rich, but enigmatic, source of mesenchymal stromal cells," Stem Cells Translational Medicine, vol. 6, no. 7, pp. 1620-1630, 2017.
[8] K. Sobolewski, E. Bankowski, L. Chyczewski, and S. Jaworski, "Collagen and glycosaminoglycans of Wharton's jelly," Neonatology, vol. 71, no. 1, pp. 11-21, 1997.
[9] H.-S. Wang, et al.S.-C. Hung, S.-T. Peng et al., "Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord," Stem Cells, vol. 22, no. 7, pp. 1330-1337, 2004.
[10] I. Kalaszczynska and K. Ferdyn, "Wharton's jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance," BioMed Research International, vol. 2015, Article ID 430847, 11 pages, 2015.
[11] M. Dominici, K. le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
[12] S. Tipnis, C. Viswanathan, and A. S. Majumdar, "Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO," Immunology & Cell Biology, vol. 88, no. 8, pp. 795-806, 2010.
[13] X. Y. Wang, Y. Lan, W. Y. He et al., "Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos," Blood, vol. 111, no. 4, pp. 2436-2443, 2008.
[14] J.-Y. Hsieh, Y.-S. Fu, S.-J. Chang, Y.-H. Tsuang, and H.W. Wang, "Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton's jelly of umbilical cord," Stem Cells and Development, vol. 19, no. 12, pp. 1895-1910, 2010.
[15] T. Hou, J. Xu, X. Wu et al., "Umbilical cord Wharton's jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering," Tissue Engineering Part A, vol. 15, no. 9, pp. 2325-2334, 2009.
[16] K. Baba, Y. Yamazaki, S. Ikemoto, K. Aoyagi, A. Takeda, and E. Uchinuma, "Osteogenic potential of human umbilical cord-derived mesenchymal stromal cells cultured with umbilical cord blood-derived autoserum," Journal of CranioMaxillofacial Surgery, vol. 40, no. 8, pp. 768-772, 2012.
[17] G. la Rocca, M. Lo Iacono, T. Corsello, S. Corrao, F. Farina, and R. Anzalone, "Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy," Current Stem Cell Research & Therapy, vol. 8, no. 1,pp. 100-113, 2013.
[18] M. Esposito, A. Lucariello, C. Costanzo et al., "Differentiation of human umbilical cord-derived mesenchymal stem cells, WJ-MSCs, into chondrogenic cells in the presence of pulsed electromagnetic fields," In Vivo, vol. 27, no. 4, pp. 495-500, 2013.
[19] M. Messerli, A. Wagner, R. Sager et al., "Stem cells from umbilical cord Wharton's jelly from preterm birth have neuroglial differentiation potential," Reproductive Sciences, vol. 20, no. 12, pp. 1455-1464, 2013.
[20] Y. B. Cui, S. S. Ma, C. Y. Zhang et al., "Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer's disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis," Behavioural Brain Research, vol. 320, pp. 291-301, 2017.
[21] I. Garzon, M. A. Martin-Piedra, C. Alfonso-Rodriguez et al., "Generation of a biomimetic human artificial cornea model using wharton's jelly mesenchymal stem cells," Investigative Opthalmology & Visual Science, vol. 55, no. 7, pp. 4073-4083, 2014.
[22] J. Hu, Y. Wang, H. Gong et al., "Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes," Experimental and Therapeutic Medicine, vol. 12, no. 3, pp. 1857-1866, 2016.
[23] M. L. Weiss, et al.C. Anderson, S. Medicetty et al., "Immune properties of human umbilical cord Wharton's jelly-derived cells," Stem Cells, vol. 26, no. 11, pp. 2865-2874, 2008.
[24] F. Granero-Molto, J. A. Weis, M. I. Miga et al., "Regenerative effects of transplanted mesenchymal stem cells in fracture healing," Stem Cells, vol. 27, no. 8, pp. 1887-1898, 2009.
[25] H. Kaneki, R. Guo, D. Chen et al., "Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts," Journal of Biological Chemistry, vol. 281, no. 7, pp. 4326-4333, 2006.
[26] X. Zhou, et al.Z. Zhang, J. Q. Feng et al., "Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 29, pp. 12919-12924, 2010.
[27] Y.-i. Kawabe, Y. X. Wang, I. W. McKinnell, M. T. Bedford, and M. A. Rudnicki, "Carm1 regulates Pax7 transcriptional activity through MLL1/2 recruitment during asymmetric satellite stem cell divisions," Cell Stem Cell, vol. 11, no. 3, pp. 333-345, 2012.
[28] S. J. Prasanna, D. Gopalakrishnan, S. R. Shankar, and A. B. Vasandan, "Pro-inflammatory cytokines, IFN[gamma] and TNF[alpha], influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially," PLoS One, vol. 5, no. 2, article e9016, 2010.
[29] T. Deuse, M. Stubbendorff, K. Tang-Quan et al., "Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells," Cell Transplantation, vol. 20, no. 5, pp. 655-667, 2011.
[30] R. Sarugaser, D. Lickorish, D. Baksh, M. M. Hosseini, and J. E. Davies, "Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors," Stem Cells, vol. 23, no. 2, pp. 220-229, 2005.
[31] S. B. Goodman, P. Huie, Y. Song et al., "Cellular profile and cytokine production at prosthetic interfaces: study of tissues retrieved from revised hip and knee replacements," The Journal of Bone and Joint Surgery, vol. 80, no. 3, pp. 531-539, 1998.
[32] N. M. Moll and R. M. Ransohoff, "CXCL12 and CXCR4 in bone marrow physiology," Expert Review of Hematology, vol. 3, no. 3, pp. 315-322, 2010.
[33] E. C. Butcher and L. J. Picker, "Lymphocyte homing and homeostasis," Science, vol. 272, no. 5258, pp. 60-67, 1996.
[34] L. da Silva Meirelles, A. M. Fontes, D. T. Covas, and A. I. Caplan, "Mechanisms involved in the therapeutic properties of mesenchymal stem cells," Cytokine & Growth Factor Reviews, vol. 20, no. 5-6, pp. 419-427, 2009.
[35] S. Zwingenberger, Z. Yao, A. Jacobi et al., "Enhancement of BMP-2 induced bone regeneration by SDF-1a mediated stem cell recruitment," Tissue Engineering Part A, vol. 20, no. 3-4, pp. 810-818, 2014.
[36] I. Majore, P. Moretti, F. Stahl, R. Hass, and C. Kasper, "Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord," Stem Cell Reviews and Reports, vol. 7, no. 1, pp. 17-31, 2011.
[37] S. Karahuseyinoglu, O. Cinar, E. Kilic et al., "Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys," Stem Cells, vol. 25, no. 2, pp. 319-331, 2007.
[38] D. J. Hadjidakis and I. I. Androulakis, Bone Remodeling, Annals of the New York Academy of Sciences, 2006.
[39] U. Kini and B. N. Nandeesh, "Physiology of bone formation, remodeling, and metabolism," in Radionuclide and Hybrid Bone Imaging, pp. 29-57, Springer, Berlin, Heidelberg, 2012.
[40] L. J. Raggatt and N. C. Partridge, "Cellular and molecular mechanisms of bone remodeling," Journal of Biological Chemistry, vol. 285, no. 33, pp. 25103-25108, 2010.
[41] S. Kohli and V. Kohli, "Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications," Indian Journal of Endocrinology and Metabolism, vol. 15, no. 3, pp. 175-181, 2011.
[42] T. L. Andersen, M. E. Abdelgawad, H. B. Kristensen et al., "Understanding coupling between bone resorption and formation," The American Journal of Pathology, vol. 183, no. 1, pp. 235-246, 2013.
[43] M. Borhani-Haghighi, T. Talaei-Khozani, M. Ayatollahi, and Z. Vojdani, "Wharton's jelly-derived mesenchymal stem cells can differentiate into hepatocyte-like cells by HepG2 cell line extract," Iranian Journal of Medical Sciences, vol. 40, no. 2, pp. 143-151, 2015.
[44] D. Bharti, S. B. Shivakumar, J.-K. Park et al., "Comparative analysis of human Wharton's jelly mesenchymal stem cells derived from different parts of the same umbilical cord," Cell and Tissue Research, vol. 372, no. 1, pp. 51-65, 2018.
[45] D. T. Denhardt and M. Noda, "Osteopontin expression and function: role in bone remodeling," Journal of Cellular Biochemistry, vol. 72, no. S30-S31, pp. 92-102, 1998.
[46] J. Klein-Nulend, J. Roelofsen, C. M. Semeins, A. L. J. J. Bronckers, and E. H. Burger, "Mechanical stimulation of osteopontin mRNA expression and synthesis in bone cell cultures," Journal of Cellular Physiology, vol. 170, no. 2, pp. 174-181, 1997.
[47] T. M. Liu and E. H. Lee, "Transcriptional regulatory cascades in Runx2-dependent bone development," Tissue Engineering Part B: Reviews, vol. 19, no. 3, pp. 254-263, 2013.
[48] T. Komori, "Signaling networks in RUNX2-dependent bone development," Journal of Cellular Biochemistry, vol. 112, no. 3, pp. 750-755, 2011.
[49] T. Komori, H. Yagi, S. Nomura et al., "Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts," Cell, vol. 89, no. 5, pp. 755-764, 1997.
[50] Q. Tu, J. Zhang, L. James et al., "Cbfa1/Runx2-deficiency delays bone wound healing and locally delivered Cbfa1/Runx2 promotes bone repair in animal models," Wound Repair and Regeneration, vol. 15, no. 3, pp. 404-412, 2007.
[51] J. H. Jonason, G. Xiao, M. Zhang, L. Xing, and D. Chen, "Posttranslational regulation of Runx2 in bone and cartilage," Journal of Dental Research, vol. 88, no. 8, pp. 693-703, 2009.
[52] R. T. Franceschi, G. Xiao, D. Jiang, R. Gopalakrishnan, S. Yang, and E. Reith, "Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation," Connective Tissue Research, vol. 44, no. 1, pp. 109-116, 2003.
[53] M. D. Yazid, S. H. Z. Ariffin, S. Senafi, M. A. Razak, and R. M. A. Wahab, "Determination of the differentiation capacities of murines' primary mononucleated cells and MC3T3-E1 cells," Cancer Cell International, vol. 10, no. 1, p. 42, 2010.
[54] F. Ng, S. Boucher, S. Koh et al., "PDGF, TGF-[beta], and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages," Blood, vol. 112, no. 2, pp. 295-307, 2008.
[55] G. Xiao, D. Jiang, P. Thomas et al., "MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1," Journal of Biological Chemistry, vol. 275, no. 6, pp. 4453-4459, 2000.
[56] N. Rucci, "Molecular biology of bone remodelling," Clinical Cases in Mineral and Bone Metabolism, vol. 5, no. 1, pp. 49-56, 2008.
[57] L. F. Bonewald and G. R. Mundy, "Role of transforming growth factor-beta in bone remodeling," Clinical Orthopaedics and Related Research, no. 250, pp. 261-276, 1990.
[58] J. M. Hock, M. Centrella, and E. Canalis, "Insulin-like growth factor I has independent effects on bone matrix formation and cell replication," Endocrinology, vol. 122, no. 1, pp. 254-260, 1988.
[59] R. M. Locklin, R. O. Oreffo, and J. T. Triffitt, "Effects of TGF[beta] and BFGF on the differentiation of human bone marrow stromal fibroblasts," Cell Biology International, vol. 23, no. 3, pp. 185-194, 1999.
[60] E. Torreggiani, G. Lisignoli, C. Manferdini et al., "Role of slug transcription factor in human mesenchymal stem cells," Journal of Cellular and Molecular Medicine, vol. 16, no. 4, pp. 740-751, 2012.
[61] A. Szepesi, Z. Matula, A. Szigeti et al., "In vitro characterization of human mesenchymal stem cells isolated from different tissues with a potential to promote complex bone regeneration," Stem Cells International, vol. 2016, Article ID 3595941, 9 pages, 2016.
[62] A. Subramanian, C. Y. Fong, A. Biswas, and A. Bongso, "Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton's jelly compartment provides the best source of clinically utilizable mesenchymal stem cells," PLoS One, vol. 10, no. 6, article e0127992, 2015.
[63] F. Bustos, H. Sepulveda, C. P. Prieto et al., "Runt-related transcription factor 2 induction during differentiation of Wharton's jelly mesenchymal stem cells to osteoblasts is regulated by Jumonji AT-rich interactive domain 1B histone demethylase," Stem Cells, vol. 35, no. 12, pp. 2430-2441, 2017.
[64] Z. Qu, S. Mi, and G. Fang, "Clinical study on treatment of bone nonunion with MSCs derived from human umbilical cord," Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, vol. 23, no. 3, pp. 345-347, 2009.
[65] P. Li, K. Cui, B. Zhang et al., "Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members," International Journal of Molecular Medicine, vol. 35, no. 4, pp. 1051-1057, 2015.
[66] I. H. Dilogo, M. R. A. Primaputra, J. A. Pawitan, and I. K. Liem, "Modified Masquelet technique using allogeneic umbilical cord-derived mesenchymal stem cells for infected non-union femoral shaft fracture with a 12 cm bone defect: a case report," International Journal of Surgery Case Reports, vol. 34, pp. 11-16, 2017.
[67] J. Cai, Z. Wu, L. Huang et al., "Cotransplantation of bone marrow mononuclear cells and umbilical cord mesenchymal stem cells in avascular necrosis of the femoral head," Transplantation Proceedings, vol. 46, no. 1, pp. 151-155, 2014.
[68] M. Shi, S. Yu, R. Xu, and F. S. Wang, "Human mesenchymal stem cell therapy is feasible for liver cirrhosis associated with HBV infection," Hepatology International, vol. 10, no. 1, pp. S341-S342, 2016.
[69] N. Morishima, K. Nakanishi, K. Tsuchiya, T. Shibata, and E. Seiwa, "Translocation of Bim to the endoplasmic reticulum (ER) mediates ER stress signaling for activation of caspase-12 during ER stress-induced apoptosis," Journal of Biological Chemistry, vol. 279, no. 48, pp. 50375-50381, 2004.
[70] A. Patel and N. Riordan, "Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with duchenne muscular dystrophy (DMD)," Cytotherapy, vol. 17, no. 6, article S46, 2015.
[71] D.-W. Kim, M. Staples, K. Shinozuka, P. Pantcheva, S.D. Kang, and C. Borlongan, "Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications," International Journal of Molecular Sciences, vol. 14, no. 6, pp. 11692-11712, 2013.
[72] A. Can, F. T. Celikkan, and O. Cinar, "Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials," Cytotherapy, vol. 19, no. 12, pp. 1351-1382, 2017.
[73] M. S. Choudhery, M. Badowski, A. Muise, J. Pierce, and D. T. Harris, "Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation," Journal of Translational Medicine, vol. 12, no. 1, p. 8, 2014.
[74] O. Karadas, D. Yucel, H. Kenar, G. Torun Kose, and V. Hasirci, "Collagen scaffolds with in situ-grown calcium phosphate for osteogenic differentiation of Wharton's jelly and menstrual blood stem cells," Journal of Tissue Engineering and Regenerative Medicine, vol. 8, no. 7, pp. 534-545, 2014.
[75] M. Torkaman, M. Ghollasi, M. Mohammadnia-Afrouzi, A. Salimi, and A. Amari, "The effect of transplanted human Wharton's jelly mesenchymal stem cells treated with IFN-[gamma] on experimental autoimmune encephalomyelitis mice," Cellular Immunology, vol. 311, pp. 1-12, 2017.
[76] K. O'Donoghue, M. Choolani, J. Chan et al., "Identification of fetal mesenchymal stem cells in maternal blood: implications for non-invasive prenatal diagnosis," Molecular Human Reproduction, vol. 9, no. 8, pp. 497-502, 2003.
[77] D. Baksh, R. Yao, and R. S. Tuan, "Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow," Stem Cells, vol. 25, no. 6, pp. 1384-1392, 2007.
[78] I. Arutyunyan, A. Elchaninov, A. Makarov, and T. Fatkhudinov, "Umbilical cord as prospective source for mesenchymal stem cell-based therapy," Stem Cells International, vol. 2016, Article ID 6901286, 17 pages, 2016.
[79] J. Lim, Z. R. M. Razi, J. Law, A. M. Nawi, R. B. H. Idrus, and M. H. Ng, "MSCs can be differentially isolated from maternal, middle and fetal segments of the human umbilical cord," Cytotherapy, vol. 18, no. 12, pp. 1493-1502, 2016.
[80] S. Kargozar, M. Mozafari, S. J. Hashemian et al., "Osteogenic potential of stem cells-seeded bioactive nanocomposite scaffolds: a comparative study between human mesenchymal stem cells derived from bone, umbilical cord Wharton's jelly, and adipose tissue," Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 106, no. 1, pp. 61-72, 2018.
[81] M. R. Todeschi, R. el Backly, C. Capelli et al., "Transplanted umbilical cord mesenchymal stem cells modify the in vivo microenvironment enhancing angiogenesis and leading to bone regeneration," Stem Cells and Development, vol. 24, no. 13, pp. 1570-1581, 2015.
[82] L. Polo-Corrales, M. Latorre-Esteves, and J. E. Ramirez-Vick, "Scaffold design for bone regeneration," Journal of Nanoscience and Nanotechnology, vol. 14, no. 1, pp. 15-56, 2014.
[83] A. K. Batsali, C. Pontikoglou, D. Koutroulakis et al., "Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells," Stem Cell Research & Therapy, vol. 8, no. 1, p. 102, 2017.
[84] A. Zajdel, M. Kalucka, E. Kokoszka-Mikolaj, and A. Wilczok, "Osteogenic differentiation of human mesenchymal stem cells from adipose tissue and Wharton's jelly of the umbilical cord," Acta Biochimica Polonica, vol. 64, no. 2, pp. 365-369, 2017.
[85] R. K. Schneider, A. Puellen, R. Kramann et al., "The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in threedimensional collagen scaffolds," Biomaterials, vol. 31, no. 3, pp. 467-480, 2010.
[86] S. Bose, M. Roy, and A. Bandyopadhyay, "Recent advances in bone tissue engineering scaffolds," Trends in Biotechnology, vol. 30, no. 10, pp. 546-554, 2012.
[87] H. W. Sun, R. J. Feigal, and H. H. Messer, "Cytotoxicity of glutaraldehyde and formaldehyde in relation to time of exposure and concentration," Pediatric Dentistry, vol. 12, no. 5, pp. 303-307, 1990.
[88] S. Mechiche Alami, H. Rammal, C. Boulagnon-Rombi et al., "Harnessing Wharton's jelly stem cell differentiation into bone-like nodule on calcium phosphate substrate without osteoinductive factors," Acta Biomaterialia, vol. 49, pp. 575-589, 2017.
[89] L. Penolazzi, S. Mazzitelli, R. Vecchiatini et al., "Human mesenchymal stem cells seeded on extracellular matrix-scaffold: viability and osteogenic potential," Journal of Cellular Physiology, vol. 227, no. 2, pp. 857-866, 2012.
[90] K. E. Mitchell, M. L. Weiss, B. M. Mitchell et al., "Matrix cells from Wharton's jelly form neurons and glia," Stem Cells, vol. 21, no. 1, pp. 50-60, 2003.
[91] Y. S. Fu, C. H. Lu, K. A. Chu et al., "Xenograft of human umbilical mesenchymal stem cells from Wharton's jelly differentiating into osteocytes and reducing osteoclast activity reverses osteoporosis in ovariectomized rats," Cell Transplantation, vol. 27, no. 1, pp. 194-208, 2018.
[92] F. E. Al Jofi, T. Ma, D. Guo et al., "Functional organic cation transporters mediate osteogenic response to metformin in human umbilical cord mesenchymal stromal cells," Cytotherapy, vol. 20, no. 5, pp. 650-659, 2018.
[93] A. Ramesh, M. M. Kanafi, and R. R. Bhonde, "Modulus-dependent characteristics of Wharton's jelly mesenchymal stem cells (WJMSC) encapsulated in hydrogel microspheres," Journal of Biomaterials Science, Polymer Edition, vol. 25, no. 17, pp. 1946-1961, 2014.
[94] L. Wang, L. Zhao, and M. S. Detamore, "Human umbilical cord mesenchymal stromal cells in a sandwich approach for osteochondral tissue engineering," Journal of Tissue Engineering and Regenerative Medicine, vol. 5, no. 9, pp. 712-721, 2011.
Ayu Suraya Ansari, (1) Muhammad Dain Yazid, (2) Nur Qisya Afifah Veronica Sainik, (1) Rabiatul Adawiyah Razali, (1) Aminuddin Bin Saim, (3) and Ruszymah Bt Hj Idrus [ID] (1)
(1) Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia
(2) Tissue Engineering Centre, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia
(3) Ear, Nose & Throat Consultant Clinic, Ampang Puteri Specialist Hospital, 68000 Ampang, Selangor, Malaysia
Correspondence should be addressed to Ruszymah Bt Hj Idrus; ruszyidrus@gmail.com
Received 19 May 2018; Revised 27 July 2018; Accepted 3 September 2018; Published 11 November 2018
Academic Editor: Jeong-Chae Lee
Caption: Figure 1: Anatomical compartment of Wharton's jelly mesenchymal stem cell.
Caption: Figure 2: Mechanism of bone regeneration and activation of signaling pathways.
Caption: Figure 3: Flow chart of the article selection process using the Scopus and MEDLINE databases.
Table 1: Summary and classification of the 18 articles selected
from the database search.
No. Author and Type of Subject/sample
year study
1. Fu et al. In vitro (i) Human umbilical
2018 [91] and cord-derived
in vivo mesenchymal stem
cells (UC-MSCs)
(ii) Sprague-Dawley's
osteoblast
(iii) Sprague-Dawley 's
osteoclast
2. Al Jofi et al. In vitro (i) Wharton's jelly
2018 [92] mesenchymal stem
cells (WJ-MSCs)
3. Bharti et al. In vitro (i) Wharton's jelly
(2018) [44] mesenchymal stem
cells (WJ-MSCs)
4. Batsali et al. In vitro (i) Bone marrow
2017 [83] mesenchymal stem
cell (BM-MSCs)
(ii) Wharton's jelly
mesenchymal stem
cells (WJ-MSCs)
5. Zajdel et al. In vitro (i) Adipose tissue (AT-
2017 [84] MSCs)
(ii) WJ-MSCs
6. Mechiche In vitro
Alami et al.
2017 [88]
7. Szepesi et al. In vitro (i) WJ-MSCs
2016 [61] (ii) AT-MSCs
(iii) Periodontal
ligament MSCs
(PDL-MSCs)
8. Lim et al. In vitro Human WJ-MSCs
2016 [79] (i) Fetal segment
(ii) Maternal segment
(iii) Middle segment
9. Kargozar In vitro (i) BM-MSCs
et al. 2018 and (ii) AT-MSCs
[80] in vivo (iii) UC-MSCs
10. Todeschi In vivo (i) UC-MSCs
et al. 2015 (ii) BM-MSCs
[81]
11. Karadas In vitro (i) WJ-MSCs
et al. 2014 (ii) BM-MSCs
[74] (iii) Menstrual blood
mesenchymal stem
cells (MBMSCs)
12. Ramesh In vitro (i) WJ-MSCs
et al. 2014
[93]
13. Baba et al. In vivo & Human umbilical cord
2012 [16] in vitro mesenchymal stem cells
(hUC-MSCs)
14. Penolazzi In vitro (i) WJ-MSCs
et al. 2012
[89]
15. Wang et al. In vitro (i) UC-MSCs
2011 (94)
16. Schneider et In vitro Human mesenchymal
al. 2010 stem cells (hMSC):
[85] (i) UC-MSCs
(ii) BM-MSCs
17. Hsieh et al. (i) In (i) WJ-MSCs
2010 [14] vitro (ii) BM-MSCs
18. Hou et al. (i) In (i) hUC-MSCs
2009 [15] vitro (ii) BM-MSCs
No. Induction factor WJ-MSC isolation
method
1. Differentiation medium (i) Enzymatic
Osteogenic medium: digestion
(1) High-glucose DMEM (ii) Part of UC: not
(2) 10% serum mentioned
(3) [10.sup.8] M dexamethasone
(4) 50 ng/mL L-ascorbic acid
(5) 10 mM [beta]-glycerophosphate
Osteoclast differentiation
(1) 10 or 100 ng RANKL
2. (i) Commercial UC-MSCs
(i) 10 [micro]mol/L metformin
(antidiabetic drag) (ii) Part of UC: not
mentioned
3. (i) Osteogenic medium (i) Explant method
(1) ADMEM (ii) Part of UC:
(2) 0.1 mM dexamethasone maternal, middle
(3) 50 mM ascorbic acid and fetal
(4) 10 mM glycerol-2-phosphate
(ii) Adipogenic medium:
(1) ADMEM
(2) 500 mM isobutyl
methylxanthine
(3) 1 mM dexamethasone
(4) Insulin
(5) 100 mM indomethacin
(6) 10 mM insulin
(iii) Chondrogenic medium using
comer
(1) StemPro1Osteocyte/
Chondrocyte Di?erentiation Basal
Medium; StemPro1
Chondrogenesis supplement;
Gibco).
(2) Hepatocyte
(3) ADMEM
(4) 2% FBS
(5) 10 ng/ml of oncostatin M
(6) 10 nmol/L dexamethasone
(7) 1% insulin transferrin-
selenium
4. Differentiation medium: (i) Explant method
Osteogenic medium: (ii) Part of UC:
(1) High-glucose DMEM maternal, middle,
(2) 10% serum and fetal
(3) [10.sup.7]M dexamethasone segments
(4) 25 [micro]g/mL L-ascorbic add
(5) 3 mM NapH.sub.2]P[O.sub.4]
5. Osteogenic medium (Lonza): (i) Commercial AT-
(1) Dexamethasone MSCs and UC-
(2) Ascorbic acid MSCs
(3) [beta]-Glycerophosphate (ii) Part of UC: not
mentioned
6. Calcium phosphate (CaP) substrate (i) Commercial UC-
build-up (without osteogenic MSCs
induction (ii) Part of UC: not
mentioned
7. Di?erentiation medium: (i) Enzymatic
(i) StemPro Osteogenesis digestion UC-
Di?erentiation kit MSCs
(ii) StemPro Chondrogenesis (ii) Part of UC: not
Di?erentiation kit mentioned
(iii) StemPro Adipogenesis
Di?erentiation kit
(iv) Endothelial Cell Growth
Medium
8. (i) Osteogenic medium (i) Enzymatic
(1) Alpha-MEM digestion
(2) Dexamethasone (ii) Maternal, middle,
(3) Ascorbic acid and fetal
(4) /3-Glycerol phosphate segments
(ii) Adipogenic medium:
(1) DMEM/F12
(2) 3--Isobutyl -3 -methylxanthine
(3) Dexamethasone
(4) Insulin
(iii) Chondrogenic medium
(1) Alpha-MEM
(2) Transforming growth factor 3
(TGP-[beta]3)
9. (i) Nanocomposite sca?olds (3D (i) Enzymatic
bioactive glass-gelatin sca?olds digestion
(BaG-Gel) consisting of (ii) Part of UC: not
Si[O.sub.2]-[P.sub.2][O.sub.5]- mentioned
CaO (64% Si[O.sub.2],
5%[P.sub.2][O.sub.5], and 31%
CaO).
10. (i) Ceramic sca?olds (Skelite; (i) Explant method
4 x 4 x 4 mm cubes of 33% (ii) Part of UC: not
hydroxyapatite and 67% silicon- mentioned
stabilized tricalcium phosphate,
Si-TCP)
(ii) Platelet-rich plasma (PRP)
(iii) Conditioned medium (CM)
11. (i) Collagen scafolds with in situ (i) Explant method
calcium phosphate (CaP) (ii) Part of UC: not
(ii) Diferentiation medium: mentioned
(1) High-glucose DMEM
(2) 10 nM dexamethasone
(3) 50 [micro]g/mL ascorbic acid
(4) 10 mM [beta]-glycerophosphate
(5) 10% FBS
(6) 100 units/mL penicillin
(7) 100 [micro]g/mL streptomycin
12. (i) Hydrogel alginate microspheres (i) Explant method
(ii) Osteogenic di?erentiation (ii) Part of UC: not
media: mentioned
(1) Basal medium
(2) 10 mM [beta]-glycerophosphate
(3) 1 mM dexamethasone
(4) 5 mg/mL ascorbic acid
13. Diferentiation medium: (i) Enzymatic
(i) NH OsteoDi Medium digestion
(ii) NH AdipoDi Medium (ii) Part of UC: not
(iii) rhBMP2 mentioned
(iv) Sca?old
14. (i) Porcine urinary bladder (i) Enzymatic
matrix (pUBM) digestion
(ii) Part of UC: not
mentioned
15. (i) Poly-L-lactic acid (PLLA) (i) Enzymatic
sca?old digestion
(ii) Osteogenic induction medium: (ii) Part of UC: not
(1) Low-glucose DMEM mentioned
(2) 10% FBS
(3) 1% penicillin/streptomycin
(4) 100 nM dexamethasone,
(5) 10 mM sodium [beta]-
glycerophosphate,
(6) 50 [micro]g/mL ascorbic acid
2-phosphate (AA2P)
(7) 10 nM 1,25-dihydroxyvitamin
D3
(i) Chondrogenic induction
medium:
(1) High-glucose DMEM (DMEM-
HG)
(2) 1% nonessential amino acids
(NEAA)
(3) 1x sodium pyruvate
(4) 1x insulin-transferrin-
selenium premix (ITS)
(5) 50 [micro]g/mL (AA2P)
(6) 40 [micro]g/mL L-proline
(7) 100 nM dexamethasone
(8) 10 ng/mL TGF-[beta]1
16. (i) Sca?old: 3D collagen gel (i) Enzymatic
(ii) Osteogenic induction medium: digestion
(1) Low-glucose DMEM (ii) Part of UC: not
(2) 10% FCS mentioned
(3) 100 nM dexamethasone
(4) 10 mM sodium [beta]-
glycerophosphate
(5) 0.05 mM/L-ascorbic acid 2-
phosphate
(iii) Adipogenic induction medium:
(1) DMEM high glucose
(2) 1 [micro]M dexamethasone
(3) 0.2 mM indomethacin
(4) 0.01 mg/mL insulin
(5) 0.5 mM 3-isobutyl-1-
methylxanthine
(6) 10% FCS
17. Osteogenic di?erentiation medium: (i) Enzymatic
(1) DMEM digestion
(2) 10% FBS (ii) Part of UC: not
(3) 0.1 mM dexamethasone mentioned
(4) 10 mM [beta]-glycerophosphate
(5) 50 mM ascorbic acid
18. (i) BMP-2 treatment: (i) Enzymatic
(a) Bone morphogenetic protein 2- digestion
blocking antibodies (BMP2 Ab) (ii) Part of UC: not
(b) Recombinant human BMP2 mentioned
(rhBMP2)
(c) Noggin
(ii) Osteogenic di?erentiation
medium:
(1) DMEM/F12
(2) 10% FBS
(3) Dexamethasone
(4) Ascorbic acid (AsA) 2-
phosphate
(5) [beta]-Glycerophosphate
(iii) Adipogenic di?erentiation
medium:
(1) DMEM/F12
(2) 1% FBS
(3) 100 nM dexamethasone
(4) 1 nM insulin
(iv) Chondrogenic di?erentiation
medium:
(1) DMEM/F12
(2) Dexamethasone
(3) AsA
(4) TGF-[beta]1
(5) ITS+
Premix
No. Results Conclusion
1. (1) MicroCT result showed that
transplantation of UC-MSCs
increased bone mass in the distal
condyle of normal rat femur
compared to other groups
(2) Goldner's staining indicated UC-MSCs able to be
that compact arrangement of di?erentiated into
collagen with less trabecular osteoblast and are safe
thickness in the group undergoes for transplantation in
implantation with UC-MSCs. A bone disease treatment.
trabeculae-like structure
containing lamellae was detected,
but there are no cell arrangements
found in the area
(3) Osteocalcin (OC) staining
showed increased osteocalcin level
in OVX-receiving UC-MSCs
(4) Antihuman-specific nuclei
antigen showed engrafted UC-MSCs
had differentiated into osteoblasts
(5) RT PCR: (i) Human osteocalcin
and abundant osterix (OSX) was
detected in ovx-receiving UC-MSCs
(6) In vitro coculture system
showed more expression of alkaline
phosphatase (ALP) if the osteoblast
is cocultured with UC-MSCs
2. Metformin-treated UC-MSCs increased OCT-expressing WJ-MSCs
in mineralization stained through have the ability to be
Alizarin Red Staining. But in OCT- di?erentiated into
1-(organic cation transporter-) osteoblasts when induced
siRNA-transfected cells, a with metformin.
significant decrease in calcium-
rich nodule formation was observed.
3. (1) Bone nodules: formed by cells WJ-MSCs are a good cell
from all segments source for autologous/
allogeneic stem cell
(2) Chondrogenic potential: source.
occurred in cells from all segments
4. (1) Osteogenic differentiation The osteogenic
(Alizarin Red and von Kossa differentiation potential
staining): WJ-MSCs showed similar of WJ-MSCs is regulated
staining potential as BM-MSC by WISPl and sFRP4,
respectively.
(2) Real-time- (RT-) PCR:
(i) Osteocyte-related gene
expression: higher expression of
Runt-related transcription factor 2
(RUNX2), distal-less homeobox
protein 5 (DLX5), osteocalcin
(OCN), and alkaline phosphatase
(ALP) by BM-MSCs
(3) Differential expression of WNT
ligands; sFRP4 (secreted frizzled-
related protein 4) and WISP1 (WNT1
-inducible signalling pathway
protein 1) were significantly
reduced in WJ-MSCs
(4) WISP1 implicated in osteogenic
differentiation; RUNX2, ALP, and
OSC were significantly upregulated
5. (1) Calcium deposition by Alizarin WJ-MSCs have the ability
Red staining to di?erentiate into the
osteogenic lineage.
(i) Calcium deposition was greater
in AT-MSCs when compared to WJ-
MSCs
(2) ALP activity
(i) ALP activity was higher in AT-
MSCs when compared to WJ-MSCs
(3) Osteoprotogerin (OPG) secretion
(i) Both osteo-induced cell types
showed high OPG secretion when
compared to control
(4) Osteocalcin (OC) secretion
(i) OC secretion was higher in WJ-
MSCs when compared to AT-MSCs
6. (1) Gene expression analysis Excellent osteogenic
potential of sprayed CaP
(i) Day 7: Runt-related and WJ-MSCs in bone
transcription factor 2 (RUNX2) and tissue engineering
secreted phosphoprotein 1 (SPP-1)
were upregulated
(ii) Day 14: collagen type 1 Alpha
1 (COL1A1) and ALP were upregulated
(iii) Day 21: bone gamma-
carboxyglutamic acid-containing
protein (BGLP) and ALP were
upregulated
(2) Nodule characterization
(i) Hematoxylin-eosin-saffron (HES)
staining revealed continuous layers
of cells at the surface of the
nodule with randomly distributed
cells embedded within fibrous
tissues
(ii) Masson's trichrome staining
showed the presence of green-
stained fibrous tissue composed of
newly formed collagen
7. (1) Osteogenic differentiation: AT- WJ-MSCs have osteogenic
MSCs and PDL-MSCs showed greater potential and are good
calcium deposition cell sources for bone
regeneration.
(2) Osteogenic differentiation
assessed via RT-PCR:
(i) Runt-related transcription
factor 2 (RUNX2): all cell types
showed high expression after
induction
(ii) Alkaline phosphatase (ALP):
AT-MSCs and PDL-MSCs showed
increased expression, but ALP was
significantly lower in WJ-MSCs
(iii) Calcium deposition: AT-MSCs
and PDL-MSCs showed greater calcium
deposition as compared to WJ-MSCs
(3) There was a significant
correlation between CD90 expression
and the levels of calcium
deposition in different MSC
isolates
8. Bone nodules: formed by cells
from all segments WJ-MSCs are a good cell
source for bone
regeneration.
9. In vitro study BM-MSCs, grown on BaG/
(1) Cell viability: Gel nanocomposite
(i) Sca?old had no signi?cant sca?olds, are possible
inhibitory e?ect on MSC sources for bone
proliferation over time regeneration.
(ii) MSC proliferation gradually
increased with incubation time
In vivo study
(1) Histological observations:
(i) H&E staining: all MSC-seeded
sca?olds successfully generated new
bone and demonstrated an ongoing
healing process at 4 and 12 weeks
after transplantation. The UC-MSC-
seeded sca?old showed signi?cantly
increased neovascularization
compared to the others
(ii) IHC staining: increased
expression of OCN and ALP in the
BM-MSC-seeded sca?old. Vascular
endothelial growth factor (VEGF)
expressed in all the groups of
treated cell-sca?old. Increased
neovascularization with the UC-
MSC-seeded sca?old
(iii) Histomorphometry: BM-MSC-
seeded sca?olds showed more bone
regeneration at 4 and 12 weeks
10. (1) Histological assessment UC-MSCs promote bone
revealed the formation an immature regeneration.
bone-like structures and compact
?brous tissue in UC-MSC-seeded
constructs
(2) Polarized light examination
revealed less organized collagen
?bers in the UC-MSC-seeded
sca?olds. The immature bone-like
matrix in UC-MSC-seeded sca?olds
was mostly ?lled with a loose
connective tissue
(3) Histological evaluation in an
orthotopic mouse model showed that
none of the bone defects had
completely closed. However, gold
MTC staining indicated the presence
of red blood cells in blood vessel-
like structures which is signi?cant
in the UC-MSC-transplanted group
(4) Osteocytes were clearly
detectable in the BMMSC-seeded
sca?olds
(5) However, human ALU sequences
were not detected in osteocytes
within the newly formed bone in the
UC-MSC implants and nonseeded
implants
11. (1) Cell proliferation assays: Collagen foam with the
use of CaP crystals
(i) WJ-MSCs on tissue culture formed in situ enhances
polystyrene (TCPS) and collagen the osteogenic induction
without CaP treatment increased of WJ-MSCs.
proliferation
(2) Cell attachment (?uorescence
staining):
(i) Good attachment of both cell
types to the sca?old
(ii) Confocal micrographs showed
that the cells were able to
penetrate into the pores
(3) Osteogenic di?erentiation:
(i) ALP assay:
(a) WJ-MSCs showed better
di?erentiation on untreated and
CaP-containing foams than in growth
medium
(b) ALP levels were higher inWJ-
MSCs grown on CaP-free foams than
on TCPS
(c) ALP activity was signi?cantly
higher in cells grown on collagen
with CaP crystals formed in situ
for both WJ-MSCs and MBMSCs (days
14 and 21) von Kossa staining:
(1) WJ-MSCs had higher ALP activity
and denser mineral deposition
compared to MBMSCs
12. (1) Characterization of WJ-MSCs encapsulated in
osteodi?erentiated WJ-MSCs via: hydrogel alginate
microspheres have
(i) Bradford assay: calcium osteogenic potential for
deposition increased in 2% alginate stem cell-based tissue
engineering.
(ii) Alizarin Red staining:
excellent matrix mineralization in
WJ-MSCs immobilized on 2% alginate
(iii) Immunocytochemical analysis
(osteocalcin): signi?cant
expression of osteocalcin in WJ-
MSC aggregates in 1.5% and 2%
alginate at day 21
(2) Genotypic analysis of
encapsulated WJ-MSCs showed that
OCN and Runx2 were upregulated in
1.5% and 2% alginate
13. (3) Osteogenic di?erentiation: UC-MSCs supplemented
strong calcium deposition with growth factors and
Adipogenic di?erentiation: lipid serum have osteogenic
droplet production di?erentiation potential
for bone regeneration.
(4) H&E staining: positive for bone
tissue producing osteocalcin (OCN)
(5) RT-PCR: high expression of
RUNX2, ALP, and OCN as compared to
undi?erentiated cells
14. (1) Proliferation assays showed The combination of WJ-
MSCs and pUBM shows the
(i) pUBM did not have an e?ect on promise of sca?olds for
cells in suspension conditions but bone regeneration.
a?ected cells cultured in adherent
conditions
(ii) Viable cells were homogenously
distributed over the entire sca?old
(2) TUNEL assays showed
(i) No apoptosis in hWJ-MSCs
cultured in agarose-coated wells
with increasing amounts of pUBM
(ii) The sca?old upregulated cyclin
D1
(iii) Matrixmetanoproteinase
(MMPI3) was lower but this did not
a?ect [beta]-catenin
(3) Morphological characterization:
(i) Scanning electron microscope
(SEM) analysis showed
(a) There was a signi?cant
interaction between the cells and
the biomaterial
(b) WJ-MSCs completely were
enveloped in pUBM particles to form
smooth spheroids, displaying an ECM
network covering the surface
(c) The cells and the biomaterial
formed a dense structure
(ii) X-ray energy-dispersive
spectroscopy (EDX) showed that
spheroids in osteogenic medium
contained high amounts of calcium
and phosphorous (high degree of
mineralization)
(iii) Transmission electron
microscopy (TEM) showed the
presence of focal contacts between
cells and the pUBM sca?old
(4) RT-PCR:
(i) RUNX2 expression was not
a?ected by pUBM, but increased upon
osteoinduction
(ii) WJ-MSCs seeded on pUBM were
able to produce Col IAI and OPN
after 21 days in osteogenic medium
(iii) WJ-MSCs showed increased ALP
activity and ability to deposit
mineralized matrix
(iv) OPN expression was higher in
cells grown on pUBM sca?olds in
osteogenic medium than in
osteogenic medium alone
15. (1) Biochemical assays were WJ-MSCs are a suitable
performed to assess cell source for a
sandwich approach
(i) DNA content: osteogenic parts strategy in osteochondral
of the C-cell-O composites had tissue engineering.
higher DNA contents than the O-O
composites and the osteogenic parts
of the C-O composites
(ii) Glycosaminoglycan (GAG)
content: all osteogenic groups had
similar GAG contents
(iii) Hydroxyproline (HYP) content:
osteogenic groups had a
signi?cantly higher HYP content
(iv) Calcium content: osteogenic
groups showed signi?cantly
increased calcium levels over time
(2) Histological analyses: positive
Alizarin Red staining in the
osteogenic group
(3) RT-PCR:
(i) Collagen type II (ColII): not
expressed in the osteogenic group
(ii) Collagen type I (ColI):
upregulated in all groups
(iii) RUNX2: increased in the
osteogenic group
(iv) Aggrecan: increased
signi?cantly in chondrogenic group
16. (1) Sca?old: UC-MSCs have a signi?cant
(i) 3D collagen gel underwent therapeutic impact in
progressive contraction bone tissue engineering
in the future.
(ii) After osteogenic
di?erentiation, collagen gels were
stronger and harder with BM-MSCs
and UC-MSCs
(2) Characterization of BM-MSCs and
UC-MSCs by
(i) Osteogenic di?erentiation: UC-
MSCs showed increased extracellular
matrix (ECM) deposition by Alizarin
Red (AR) staining
(ii) Adipogenic di?erentiation: UC-
MSCs showed a limited number of
small lipid vacuoles stained by Oil
Red O (ORO)
(iii) Immuno?uorescence: positive
expression of collagen IV and
laminin in UC-MSCs after 21 days of
osteogenic di?erentiation on
collagen gels
(iv) Immunohistochemistry analyses:
positive expression of osteopontin
(OPN) and bisphosphonate [2-(2-
pyridinyl) ethylidene-BP] (PEBP) in
the collagen gel
(3) TEM analysis:
(i) Osteogenic di?erentiation:
contraction of the collagenous
matrix on the UC-MSC-seeded
collagen surface
(ii) Adipogenic di?erentiation: UC-
MSC-derived lipid vacuoles were
small and stained with toluidine
blue
(4) RT-PCR: UC-MSCs expressed
collagen I, collagen III, collagen
IV, and laminin
(5) Cell migration: migrating UC-
MSCs appeared as spindle-shaped
cells with elongated cytoplasmic
processes
17. (1) Array data showed that both BM- WJ-MSCs are capable of
MSCs and WJ-MSCs expressed di?erentiating into the
multilineage di?erentiation osteogenic lineage, but
properties. BM-MSCs are superior.
(2) Real-time-PCR:
BM-MSCs > WJ-MSCs in terms of
(i) Adipocytic marker expression:
lipoprotein lipase (LPL), leptin,
peroxisome proliferator-activated
receptor gamma (PPAR[gamma]), and
fatty acid-binding protein 4
(FABP4)
(ii) Lipid accumulation
(3) Osteogenic di?erentiation
potential
(i) BM-MSCs > WJ-MSCs when cultured
in de?ned MesenCult
(ii) Expressed higher levels of
ALP, SPP-1, and RUNX2
18. (1) Trilineage di?erentiation BMP2-induced UC-MSCs have
good osteogenic
(i) Osteogenesis: osteonectin, ALP, di?erentiation (indicated
and RUNX2 were expressed by the activation of BMP2
signaling) and may be
(ii) Chondrogenesis: COL II, used in tissue-
collagen type X (COL X), and engineered bone.
aggrecan were expressed
(iii) Adipogenesis: adipsin, PPAR?,
and lipoprotein lipase
(2) ALP activity was signi?cantly
increased in BMP2-induced UC-MSCs
(i) Western blot revealed
activation of the BMP2 signaling
pathway in both cell types via
SMADs, p38, and extracellular
regulated kinase activation
Printer friendly
Cite/link
Email
Feedback